Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.58 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496748 | 0.86 | ROCK1 (0.50) | PARP1PTPRC | |
| SCHEMBL6923565 | 0.84 | PARP1 (0.56) | PARP1PARP10PARP11ACHE | |
| SCHEMBL3872064 | 0.81 | KDM4E (0.45) | PARP1 | |
| SCHEMBL31752914 | 0.81 | KDM4E (0.45) | PARP1 | |
| SCHEMBL27883759 | 0.81 | PARP1 (0.65) | PARP1PARP10PARP11ACHE | |
| SCHEMBL1959787 | 0.80 | PARP1 (0.44) | PARP1PARP10PARP11SLC6A4SLC6A3 | |
| SCHEMBL4998561 | 0.80 | PARP1 (0.74) | PARP1 | |
| SCHEMBL3002237 | 0.80 | PARP1 (0.63) | PARP1PARP10PARP11ACHE | |
| SCHEMBL30853838 | 0.80 | PARP1 (0.63) | PARP1PARP10PARP11ACHE | |
| SCHEMBL31305912 | 0.78 | PTPRC (0.50) | PTPRCSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115397412-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113939288-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20210340106-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210340106-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021211839-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211839-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| WO-2020198537-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198537-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4386/4885PARP10 2728/4885PARP11 2042/4885 |
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4437/4885PARP10 3119/4885PARP11 2282/4885 |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4395/4885PARP10 2732/4885PARP11 2071/4885 |
| US-20210340106-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4437/4885PARP10 3119/4885PARP11 2282/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4260/4885PARP10 3171/4885PARP11 2352/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4386/4885PARP10 2728/4885PARP11 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.